Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment
Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment
复制标题
DOI：
10.1097/01.jcp.0000104904.75206.19
复制
发表时间：
2004-02-01
影响因子：
2.9
通讯作者：
Nakamura, J
中科院分区：
文献类型：
--
作者：
Shinkai, K;Yoshimura, R;Nakamura, J
本研究的目的是探讨米那普仑和帕罗西汀对血浆儿茶酚胺代谢物水平的影响，并试图阐明这些药物在儿茶酚胺能神经元中作用机制的差异。在抑郁症患者中，我们研究了治疗前儿茶酚胺代谢物水平、服用米那普仑或帕罗西汀前后血浆儿茶酚胺代谢物水平的变化以及对这些药物的临床反应之间的关系。对米那普仑有反应者的血浆 3-甲氧基-4-羟基苯基乙二醇 (pMHPG) 预处理水平低于对米那普仑无反应者； pMHPG 水平的变化与 17 项汉密尔顿抑郁量表 (HRSD) 分数改善百分比之间也存在正相关。另一方面，对帕罗西汀有反应的人比对帕罗西汀无反应的人表现出更高的治疗前 pMHPG 水平，并且在 pMHPG 水平的变化与 HRSD 评分改善百分比之间观察到负相关。然而，在米那普仑或帕罗西汀治疗有反应者和无反应者之间，治疗前高香草酸血浆水平没有观察到显着差异。这些结果表明基线 pMHPG 水平与米那普仑与帕罗西汀治疗的临床反应之间存在关联。
The purpose of this study was to investigate the effects of milnacipran and paroxetine on plasma levels of catecholamine metabolites, and we attempted to elucidate the differences between the mechanisms of these drugs in catecholaminergic neurons. In depressed patients, we investigated the relationships among pretreatment levels of catecholamine metabolites, the changes in plasma catecholamine metabolite levels before and after administration of milnacipran or paroxetine, and clinical response to these drugs. Responders to milnacipran showed lower pretreatment levels of plasma 3-methoxy-4-hydroxyphenylglycol (pMHPG) than did nonresponders to milnacipran; there was also a positive correlation between changes in pMHPG levels and percent improvement of the score on the 17-item Hamilton Rating Scale for Depression (HRSD). On the other hand, responders to paroxetine showed higher pretreatment levels of pMHPG than did nonresponders to paroxetine, and a negative correlation was observed between changes in pMHPG levels and percent improvement of the HRSD score. However, a significant difference was not observed in the pretreatment plasma level of homovanillic acid between responders and nonresponders to treatment with milnacipran or paroxetine. These results suggest that there is an association between baseline pMHPG levels and clinical responses with respect to milnacipran versus paroxetine treatment.